GenesisCare USA - Fort Apache

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer5 trials
• Lung cancer3 trials
• Pancreatic cancer3 trials
• Acute lymphoblastic leukaemia2 trials
• Childhood cancers2 trials
• Metastatic breast cancer2 trials
• Chronic myeloid leukaemia1 trial
• Gastric and oesophageal cancer1 trial
• Kidney cancer1 trial
• Mantle cell lymphoma1 trial
• Melanoma1 trial
• Multiple myeloma1 trial
• and 2 more

Phase

• Phase 39 trials
• Phase 28 trials
• Phase 2/33 trials
• Phase 1/21 trial

Status

• Active, not recruiting15 trials
• Completed6 trials
• Recruiting2 trials

Lead sponsor

• ECOG-ACRIN Cancer Research Group6 trials
• SWOG Cancer Research Network6 trials
• National Cancer Institute (NCI)5 trials
• Alliance for Clinical Trials in Oncology4 trials
• Children's Oncology Group1 trial
• and 1 more

Running trials

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  NCT04510597· Phase 3· SWOG Cancer Research Network· Source

  Contact: John A. Ellerton (principal investigator)

• Active, not recruiting

  Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

  NCT04315324· Phase 1/2· SWOG Cancer Research Network· Source

• Active, not recruiting

  Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

  NCT04533451· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

  NCT04233866· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

  NCT04137107· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

  NCT04248452· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

  NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

  NCT04068103· Phase 2/3· NRG Oncology· Source

• Active, not recruiting

  Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

  NCT04071457· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

  NCT03654768· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928· SWOG Cancer Research Network· Source

  Contact: John A. Ellerton (principal investigator)

• Active, not recruiting

  Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

  NCT03267433· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

  NCT02595424· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881· Phase 3· SWOG Cancer Research Network· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

  NCT03602586· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916· Children's Oncology Group· Source

• Completed

  Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

  NCT03033576· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· National Cancer Institute (NCI)· Source